?? Exciting News from ACROBiosystems! ?? We are thrilled to unveil our new state-of-the-art GMP facility, purpose-built to tackle the unique challenges of the cell and gene therapy (CGT) sector with our Resilient Supply brand—your assurance of flexible, high-quality solutions coupled with steadfast global supply and comprehensive regulatory support. Resilient Highlights: - Robust Global Supply: Multi-point distribution ensures continuous availability. - Regulatory Excellence: Compliant with EU, US, and China regulations for unparalleled reliability. - Advanced GMP Quality Management: Upholds superior standards - Cost-effective outcomes. From immunotherapy and stem cells to organoids, we offer innovative products like: - CelThera? GMP T Cell Expansion Medium - iPSC Culture Solution Laminin 511 Mix & Go ECM Protein - GMP-grade DLL4 Protein for feeder-free NK cell differentiation - Regulatory-compliant rapid test kits, fully validated, significantly shortening cell therapy drug release cycles Our Resilient Supply products and solutions cover the entire drug development process from early discovery, process development and production, characterization and quality control, and safety testing, to clinical research. #CGT #CellTherapy #GeneTherapy #GMP #Biotechnology #Innovation #ACROBiosystems
ACROBiosystems
生物技术研究
Newark，Delaware 28,331 位关注者
Where Proteins and Innovation Advance Biomedicine
关于我们
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.
- 网站
-
https://www.acrobiosystems.com
ACROBiosystems的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Newark，Delaware
- 类型
- 上市公司
- 创立
- 2010
- 领域
- Proprietary HEK293 expression platform、In-house developed enzymatic and chemical biotin labeling technique、covid-19 antigens and antibodies、CAR-T、Reagents for COVID-19 vaccine development and evaluation、SARS-CoV-2 Related Kit Products、Targets for Antibody-Drug Conjugates、Hot target for bispecific antibody、CD3、Bispecific Antibody、Sars-cov-2 mutants、ADCs、Sars-cov-2 kits、Targets for CAR-T Cell Therapy、Multi-pass Transmembrane Proteins and Technology Platforms、Immune Checkpoint、Cytokine、BsAb targets、Fc Receptors、MABSOL Biotinylated Protein、Enzymes、Anti-idiotypic Antibodies、Cell Gene Therapy和GMP grade Cytokines
地点
ACROBiosystems员工
动态
-
#ACROHighlights [Featured Product] ?? CD3 T-Cell Engagers: Transforming Autoimmune Disease Treatment CD3 T-cell engagers are revolutionizing autoimmune disease therapy by precisely targeting T and B cell antigens. They enable enhanced B cell depletion and provide long-term immune regulation, opening doors to transformative treatments. At ACROBiosystems, we offer highly active CD3 protein products designed to support: ?? Antibody development ?? Screening ?? Quality control ?? Clinical pharmacokinetics Our solutions accelerate the advancement of bispecific and multispecific antibody therapies, driving innovation in autoimmune treatment. ?? Learn More About Our CD3 Products: https://smpl.is/9wjve #CD3 #Immunotherapy #AutoimmuneDiseases #BiotechInnovation #AntibodyTherapies #DrugDevelopment
-
-
#ACROHighlights [Featured Product] ?? IL-31: A Key Target in Dermatitis Drug Development The FDA’s recent approval of nemolizumab, the first IL-31 receptor antibody for adult prurigo nodularis, highlights the pivotal role of IL-31 in treating inflammatory skin diseases. IL-31 drives itch-related neuron activation, inflammation, and skin barrier damage, making it a prime therapeutic target. At ACROBiosystems, we offer high-quality IL-31/IL-31RA proteins with verified bioactivity to support antibody drug discovery and quality control efforts, advancing innovation in dermatitis treatments. ?? Learn more here: https://smpl.is/9wceb #IL31 #DermatitisTreatment #BiotechInnovation #InflammatoryDiseases #DrugDiscovery #SkinHealth
-
-
?? We are honored to receive LinkedIn's award for "Global Graduate Magnet Employer"! ?? In the life sciences field, we know that attracting global talent is crucial for successful innovation and development. We strive to build a diverse and inclusive platform with a working environment that is innovative, dynamic and globally-oriented. At the same time, we create global career development paths for our employees and adopt a variety of talent development channels in parallel. This helps our employees to grow and develop alongside our company while delivering value to human health and well-being, together. #EmployerBranding #CompanyCulture #TalentAcquisition #GoGlobal #TalentDevelopment?
-
-
?? Advancing Regenerative Medicine for Diabetes Awareness Month Regenerative medicine is leading the charge in the quest to cure diabetes. This Diabetes Awareness Month, we’re highlighting groundbreaking stem cell research and innovations in developing effective treatments. At ACROBiosystems, we’re proud to support this vital work with our high-quality Activin A, designed for the differentiation of iPSCs into pancreatic islet cells—a promising approach for diabetes treatment. ?? Together, let’s work toward a future without diabetes. ?? Learn more about our solutions here: https://lnkd.in/gG5zWvdR #DiabetesAwareness #RegenerativeMedicine #StemCellResearch #iPSCs #PancreaticIsletCells #BiotechInnovation
-
?? Simplifying Clinical Manufacturing for Cell Therapies ?? Cell therapies hold the potential to transform medicine, tackling cancers and genetic diseases once thought untreatable. Yet, manufacturing these life-saving treatments remains a key challenge. In this interview, Mike Zhang, the director of product development at ACRO with over 10 years of experience in cell therapy manufacturing, sheds light on: ?? The advancements driving cell therapies like CAR-T and iPSC-derived treatments. ?? Bridging the gap between academic breakthroughs and clinical manufacturing. ?? How industry innovations are making commercialization possible. ?? Watch the interview now to explore how ACROBiosystems supports researchers and startups in advancing cell therapies from lab to clinic. #CellTherapy #Biotechnology #GeneTherapy #ClinicalManufacturing #Innovation
-
? Announcing our ISO/IEC 17025 Accreditation! ? Our US Innovation Lab has earned ISO 17025 accreditation for our Surface Plasmon Resonance (SPR) services. This prestigious certification underscores our commitment to quality and precision, ensuring you receive dependable data for your biopharmaceutical research and development. Why ISO 17025 Matters to You - Confidence in the accuracy and reliability of your data - Compliance with global quality standards, ensuring smoother regulatory processes - Reports customized to meet your unique project and filing needs From kinetics and affinity to concentration measurements, trust us to deliver the precision and expertise you need to advance your science with confidence. Let’s innovate together! Contact us today to see how our ISO 17025 accredited SPR services can elevate your global projects. ??https://lnkd.in/g3w_RW2Y #SPR #ISO17025 #Biopharmaceuticals #AnalyticalTesting #MolecularInteractions #DrugDevelopment #ACROBiosystems #ScientificInnovation #Biotech
-
#MeetwithACRO [ACRO Conference - Malmo, Sweden] ACROBiosystems is thrilled to meet you at ATMP 2024 in Sweden! Visit us at Booth #49 to explore how our products can elevate your research and development efforts. Check out some of our cute giveaways at the booth, including our fan-favorite Llama Plush—yours to take home!
-
-
#ACROHighlights [Featured Product] ?? TL1A-DR3 (TR-FRET) Kit: Advancing TL1A Drug Discovery The TL1A-DR3 Inhibition Kit (TR-FRET) by ACROBiosystems is revolutionizing inhibitor screening with its high sensitivity, specificity, and ease of use. Leveraging Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology ensures accurate detection of biomolecular interactions by reducing background interference. This kit is a reliable tool for TL1A-DR3 drug discovery, offering repeatable and efficient results. ?? Learn more about TL1A products here: https://smpl.is/9v6f9 #TRFRET #TL1A #DrugDiscovery #BiotechInnovation #InhibitorScreening #HighThroughputAssays
-
-
#MeetwithACRO [ACROVision Webinar Series] The next ACROVision Webinar, presented by Clarence DEFFAUD of BIOTEM First Class Antibodies & Immunoassays in collaboration with Medicen Paris Region, will take place on November 19 at 13:30 CET. Register now: https://lnkd.in/gEWcH9Gi Au cours des dernières décennies, les anticorps monoclonaux ont démontré leur efficacité dans divers domaines de la recherche, du diagnostic et en thérapeutiques. Cependant, leur taille est parfois apparue comme un facteur limitant dans certaines de leur application. Cette limitation est principalement due à l'incapacité de pénétrer d'atteindre le site d’intérêt. Les anticorps à domaine unique (single domain antibody), également connus sous le nom de VHH ou nanobody, sont réputés pour être des alternatives déjà efficaces dans quelques cas et des candidats prometteurs capables de remédier aux inconvénients des anticorps conventionnels de taille normale. Outre un niveau élevé d'affinité et de sélectivité vis-à-vis de leur cible, la petite taille des VHH (~15 kDa), leur capacité de pénétration tissulaire, leur grande stabilité, leur processus de fabrication simple et économique et leur demi-vie fugace dans le système circulatoire en ont fait des candidats prometteurs pour le développement de divers types de thérapies. Leurs propriétés font également des VHH un outil de choix pour des approches diagnostiques ou en recherche avec notamment la cristallographie. BIOTEM a extrait la quintessence de plus de trois décennies de connaissances sur les VHH et l'a combinée à une approche de pointe en matière de conception et de construction de bibliothèques de phage display pour développer Quinthetic LibraryTM, une banque synthétique exclusive de VHH avec un taux de réussite exceptionnel de 87%. hashtag #acrobiosystems hashtag #BIOTEM hashtag #Medicen
此处无法显示此内容
在领英 APP 中访问此内容等